PT -期刊文章盟Rosanna Tortelli AU -西蒙娜Arcuti Chiara Zecca AU -罗伯塔巴龙盟盟——罗莎Capozzo盟玛丽亚蔷薇花坛Barulli AU -伊莎贝拉西蒙盟吉安卡洛Logroscino TI - Pseudobulbar影响(PBA)作为预测生存在肌萎缩性侧索硬化症(P5.089) DP - 2016年4月05 TA -神经病学PG - P5.089 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/P5.089.short 41首页00 - //www.ez-admanager.com/content/86/16_Supplement/P5.089.full所以Neurology2016 4月05;86 AB -目的:确定早期存在PBA ALS预后的预测以人群为基础的ALS事件队列。背景:在先前的研究PBA在疾病的早期阶段与更严重的肌萎缩性侧索硬化症表型有关。设计/方法:事件ALS情况下,诊断在2011年和2012年,根据El堆渣场标准是从未来的人口基础注册登记在阿普利亚,意大利南部。中心的神经Study-Lability规模(CNS-LS),自行测试问卷,被用来评估PBA的存在和严重性。总分范围从7 - 35。用于识别PBA分数≥13。Cox比例风险模型被用于生存分析。修改后的C-statistic审查生存数据用于模型的歧视。结果:我们招收了129名零星ALS,平均年龄为64岁(范围:26 - 84)。 44 patients (34[percnt]) had PBA (CNS-LS ≥ 13). The median follow-up was 23.9 months (range:1-57.1). At the censoring date (October 2015) 77/129 (60[percnt]), 49/85 (57.6[percnt]) and 28/44 (63.6[percnt]) patients reached the outcome (tracheostomy/death), in the whole, non-PBA and in the PBA group respectively. The median survival time was 23.9 (IQ range 13.6-48.2) months for the whole group, 25.4 (IQ range 14.5-49.5) for the non-PBA subgroup, and 22.8 (IQ range 11.0-41.1) for the PBA subgroup. Kaplan-Mejer survival curves for the two subgroups were not significantly different (long-rank: 0.52, p=0.47). Including PBA in a multivariable model with other demographic and clinical variables did not improve the discrimination ability of the model (survival c-statistic for outcome prediction at 3-years: 0.7012, 95[percnt] CI: 0.644-0.758 and 0.7014, 95[percnt] CI:0.645-0.758 without and with PBA, p=0.39). Conclusions: In our study presence of PBA, even though associated with a more severe phenotype of the disease at entry, is not a predictor of survival in ALS at three years after diagnosis.Disclosure: Dr. Tortelli has nothing to disclose. Dr. Arcuti has nothing to disclose. Dr. Barone has nothing to disclose. Dr. Zecca has nothing to disclose. Dr. Capozzo has nothing to disclose. Dr. Barulli has nothing to disclose. Dr. Simone has received personal compensation for activities with Sanofi Aventis and Biogen. Dr. Logroscino has received personal compensation in an editorial capacity for Karger.Wednesday, April 20 2016, 8:30 am-7:00 pm